流感药扎堆的时代，人们为什么首选奥司他韦

Core Viewpoint - Oseltamivir remains the preferred choice among various new antiviral drugs for influenza in the 2025 flu season due to its affordability, broad applicability, authoritative recommendations, and strong supply availability [1]. Group 1: Market Position and Demand - In December 2025, pediatric clinics experienced long queues of parents seeking treatment for their children, with many doctors prescribing Oseltamivir [2]. - Despite the emergence of several new antiviral drugs, Oseltamivir continues to be the most commonly used medication for influenza treatment, thanks to its solid efficacy, low price, and wide accessibility [4]. - The demand for Oseltamivir surges every winter during flu season, as families face significant financial considerations when choosing medications [8]. Group 2: Economic and Accessibility Advantages - Oseltamivir is significantly cheaper than newer antiviral drugs, with a typical box costing only a few dozen yuan, while newer drugs can cost hundreds of yuan per treatment course [9]. - The economic efficiency of Oseltamivir is particularly beneficial during influenza pandemics, as it allows for broader treatment coverage without overwhelming healthcare budgets [9]. - Oseltamivir is a staple in major hospitals and is also available in county-level hospitals and community health centers, ensuring timely access for patients across different regions [9]. Group 3: Safety and Efficacy - Since its launch in 1999, Oseltamivir has demonstrated safety and efficacy through various influenza outbreaks, making it a reliable option for vulnerable populations [11]. - Oseltamivir is suitable for a wide range of patients, including children as young as two weeks old, pregnant women, and those with underlying health conditions, which enhances its appeal as a family treatment option [12]. - The drug's long-term safety data is particularly important for high-risk groups, as it has been shown to be effective and safe for use in these populations [12]. Group 4: Guidelines and Recommendations - Multiple expert consensus guidelines in China recommend Oseltamivir as a first-line treatment for influenza, especially for high-risk groups [14]. - The latest clinical practice guidelines emphasize Oseltamivir's role as the preferred medication for severe cases, children, and pregnant women, based on substantial clinical evidence [15][16]. Group 5: Brand Trust and Market Leadership - Eastsun Pharmaceutical is the largest global producer of Oseltamivir, with its products being widely recognized and trusted by both doctors and patients [21]. - The company has invested significantly in the quality management of Oseltamivir production, ensuring that its products meet high standards and are readily available across various distribution channels [22]. - Eastsun's commitment to quality and accessibility has established "Kewai" as a household name, making it a key player in ensuring sufficient supply during flu outbreaks [22].